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Sir,
Intravitreal ganciclovir injections in aqueous
cytomegalovirus DNA positive hypertensive iritis
Teoh et al1 suggested that Posner–Schlossman Syndrome
(PSS) may represent a spectrum of anterior chamber
inflammatory responses to local viral reactivation of
members of herpesviridae family such as CMV and HSV.
We would like to share a similar case of CMV associated
hypertensive iritis treated with intravitreal ganciclovir.
A 42-year-old Chinese man initially presented with a
3-day history of right eye redness and pain. Best-
corrected visual acuity was 6/9 and intraocular pressure
was 45 mmHg. Right eye slit-lamp examination showed
mild corneal oedema, medium-sized stellate keratic
precipitate, and mild anterior chamber reaction.
Gonioscopy showed open angle. No glaucomatous optic
disc changes were present and Humphrey visual fields
were normal. The rest of the ocular examinations of both
eyes were normal. On direct questioning, patient
admitted having two mild episodes of visual blurring,
discomfort, and redness in his right eye, each lasting 1–2
days, over the past 2 years. A tentative diagnosis of PSS
was made. Topical corticosteroids and timolol were
prescribed for ocular hypertension and inflammation.
The right eye returned to normal after 2 weeks.
After 1 year, he presented with a recurrence. The right
intraocular pressure was again high at 50 mmHg. The
condition was again controlled with topical steroids and
timolol.
A relapse recurred 2 months later when the frequency
of topical steroid was reduced. To exclude an infective
cause, the aqueous was aspirated for polymerase chain
reaction (PCR) analysis. The right aqueous had CMV
DNA measured at 7.16 103 copies per ml. The left
aqueous was negative for CMV. HIV test on the patient
was negative. His CD4 and CD8 counts were normal. The
serum IgG but not the IgM to CMV was positive, the
serum CMV antigen was negative. He was recommended
to take ganciclovir but was unhappy with the diagnosis
and the expenses involved. He subsequently agreed to
try an intravitreal injection of ganciclovir. Right eye
aqueous was retested 2 weeks later and the CMV DNA
count had been reduced to 1.3 103 copies per ml. The
patient had a quiet anterior chamber and intraocular
pressures were within normal range. We think our case
adds to the evidence of herpesviridae viruses playing a
significant role in the etiology of PSS. We look forward to
further interesting reports on this subject.
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Sir,
Intravitreal triamcinolone acetonide as an adjunct
in the treatment of severe ocular toxoplasmosis
Toxoplasmosis lesions in the posterior pole are generally
treated with anti-Toxoplasma drugs in association with
high-dose oral corticosteroids.1 Our standard therapeutic
regimen consists of a 6-week course of pyrimethamine,
sulphadiazine, folinic acid, and oral prednisone, along
with topical drops. However, there are situations in
which systemic corticosteroids are contraindicated.
Herein we report two such cases, treated with anti-
Toxoplasma drugs and an intravitreal triamcinolone
acetonide (IVTA) injection.
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Case reports
A 30-year-old woman had central serous
chorioretinopathy OD associated with high-dose
corticosteroid use and active macular toxoplasmosis OS
(Figure 1). At 7 days before presentation, she was started
on pyrimethamine 25 mg daily, sulphadiazine 2 g daily,
folinic acid 5 mg twice weekly, and prednisone 60 mg
daily. Visual acuity was 20/50 OD and counting fingers
OS. Oral prednisone was discontinued and 4 mg of
triamcinolone acetonide was injected via pars plana OS
under topical anesthesia. After 5 days, marked
amelioration of the vitritis was seen, with visual acuity of
20/200 OS. At 1 month following the injection, visual
acuity was 20/20 OD and 20/100 OS. Funduscopy was
normal OD and disclosed a scarred toxoplasmosis lesion
in the superotemporal macula OS (Figure 2). The
medication was switched to oral trimethoprim-
sulphamethoxazole (160/800 mg) three times a week for
3 months. At 18 months after IVTA injection, no signs of
recurrence were noted.
A 74-year-old difficult controlled diabetic man with
active macular toxoplasmosis, along with severe anterior
chamber reaction and vitritis OS, had visual acuity of
20/20 OD and hand movements OS. Pyrimethamine,
sulphadiazine, and folinic acid were started. After 1
week, the picture was unchanged. In total, 4 mg of
triamcinolone acetonide was injected via pars plana OS.
After 7 days, marked diminution of anterior chamber
and vitreous cells was noted. Treatment was switched to
trimethoprim-sulphametoxazole at the 5th week and
discontinued 3 months later. At 18 months following
IVTA injection, visual acuity was CF at 3 m and signs of
scarring were seen in the retinochoroidal lesion. No
evidence of recurrence or active inflammation was
detected.
Discussion
Kishore et al2 reported treating four patients with
clindamycin and dexamethasone given intravitreally
Figure 1 Initial presentation. (Left) Fundus photography of the right eye (OD) revealing a circumscribed neurosensory retinal
detachment in the posterior pole (arrows). (Right) Fundus photography of the left eye (OS) showing a whitish, fluffy lesion in the
superotemporal macula, as well as marked vitritis. Fundus details are barely visible.
Figure 2 At 1 month following IVTA injection. (Left) Fundus photography OD (normal). (Right) Fundus photography OS disclosing a
scarred toxoplasmic retinochoroiditis lesion in the superotemporal macula.
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under general or peribulbar anesthesia. However, up to
four injections were required to control the disease, and
recurrence occurred in one case during a mean follow-up
time of 17.5 months. Three patients, including the one
with recurrence, continued one systemic antitoxoplasmic
medication during follow-up.
IVTA has been efficient in rapidly decreasing
inflammation in acute sight-threatening noninfectious
uveitis.3,4 In our study, a single injection of IVTA was
used as an adjunct in the treatment of severe ocular
toxoplasmosis, with rapid and successful control of the
intraocular inflammation in both cases and no signs of
recurrence during an 18-month follow-up period.
Trimethoprim-sulphamethoxazole three times a week
was used as a prophylactic treatment against the parasite
in the period in which some triamcinolone acetonide
residue might still be present in the vitreous cavity,
potentially suppressing the immune response.
Conclusion
We suggest that IVTA should be considered as a potential
benefit to patients with severe ocular toxoplasmosis or in
which the use of systemic corticosteroids is
contraindicated and should be investigated further. To
our knowledge, this is the first report of IVTA in the
treatment of infectious uveitis.4
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Sir,
The natural history of Vigabatrin-associated visual
field defects in patients electing to continue their
medication
We read with interest the paper by Best and Acheson1
regarding the natural history of Vigabatrin-associated
visual field defects in patients electing to continue their
medication. The first cases of concentric bilateral visual
field defects in patients taking Vigabatrin were reported
in the late 1990s and since then numerous cases have
been reported worldwide. The association has grown
stronger and is now a well-accepted adverse drug effect
of Vigabatrin therapy.2–4
In 2001, the Royal College of Ophthalmologists (RCO)
published screening guidelines entitled ‘The ocular side-
effects of Vigabatrin, information and guidelines for
screening’.5 For adults, they recommend pretreatment
baseline visual field using either static suprathreshold 2
or 3 zone perimetry (Humphrey 120 point or Octopus 07)
to at least 45 radius eccentricity, or Goldman kinetic
perimetry (IIIe and I4e or I2e stimuli, as appropriate). All
patients should have 6 monthly follow-up assessments
for the first 3 years of treatment, which can then be
extended to annually in patients in whom no visual field
defects are found.
We used a questionnaire survey in the South-West of
England and Wales to investigate views of consultant
ophthalmologists on the RCO guidelines and to review
current clinical practice.
Out of 97 consultants, 54 contacted responded to the
questionnaire (response rate 56%). Consultant
ophthalmologists were asked about their experience with
Vigabatrin-related visual field screening in the year 2002–
2003. More than a third (35%) of those surveyed were
unaware that the RCO had published guidelines relating
to Vigabatrin-associated visual field defects. Only 15%
had received new referrals for baseline visual field
documentation prior to patients starting on Vigabatrin
and 41% of respondents had performed or arranged
visual field screening for patients already on Vigabatrin.
With respect to screening intervals, 51% thought that the
screening interval should be 12 months or longer, 45%
agreed with a screening interval of 6 months and 4% felt
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